Cargando…
Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol
BACKGROUND: Recent studies demonstrated the efficacy of S-1-based adjuvant chemotherapy administered for six months after curative surgery for stage III gastric cancer; however, it is unproven whether this type of combination chemotherapy is more effective than the standard adjuvant chemotherapy of...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812232/ https://www.ncbi.nlm.nih.gov/pubmed/29439671 http://dx.doi.org/10.1186/s12885-018-4109-z |
_version_ | 1783300009392865280 |
---|---|
author | Namikawa, Tsutomu Maeda, Hiromichi Kitagawa, Hiroyuki Oba, Koji Tsuji, Akihito Yoshikawa, Takaki Kobayashi, Michiya Hanazaki, Kazuhiro |
author_facet | Namikawa, Tsutomu Maeda, Hiromichi Kitagawa, Hiroyuki Oba, Koji Tsuji, Akihito Yoshikawa, Takaki Kobayashi, Michiya Hanazaki, Kazuhiro |
author_sort | Namikawa, Tsutomu |
collection | PubMed |
description | BACKGROUND: Recent studies demonstrated the efficacy of S-1-based adjuvant chemotherapy administered for six months after curative surgery for stage III gastric cancer; however, it is unproven whether this type of combination chemotherapy is more effective than the standard adjuvant chemotherapy of S-1 for one year. METHODS: This multicenter phase II study evaluate the efficacy and safety of adjuvant chemotherapy using S-1 plus oxaliplatin followed by S-1 for up to one year for curatively resected stage III gastric cancer in patients aged over 20 years. Treatment initially comprises oral fluoropyrimidine S-1 (80 mg/m(2)) administered twice daily for the first 2 weeks of a 3-week cycle. On day 1 of a second 3-week cycle, patients will receive 100 mg/m(2) of intravenous oxaliplatin followed by 80 mg/m(2) of S-1 (maximum 8 cycles). Then, the patients will receive 80 mg/m(2) of S-1 daily for 4 weeks, followed by 2 weeks of no chemotherapy. This 6-week cycle will be repeated during the first year after surgery. The primary endpoint is relapse-free survival for 3 years and secondary endpoints are safety, including the incidence of adverse events, and grading of neuropathy with each treatment cycle. The planned sample size of 75 patients is appropriate for this trial. The data will be analyzed on an intention-to-treat basis, assuming a two-sided test with a 5% level of significance. DISCUSSION: In contrast to previous trials, the current study involves administration of S-1 until one year after surgery in addition to prior S-1 plus oxaliplatin, and is the first study to evaluate the safety and efficacy of S-1 plus oxaliplatin followed by S-1 for up to one year in patients with curatively resected stage III gastric cancer. TRIAL REGISTRATION: This trial is registered in the University Hospital Medical Information Network’s Clinical Trials Registry (UMIN-CTR) registration number, R000029656 (https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029656). Registered January 24, 2017. |
format | Online Article Text |
id | pubmed-5812232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58122322018-02-15 Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol Namikawa, Tsutomu Maeda, Hiromichi Kitagawa, Hiroyuki Oba, Koji Tsuji, Akihito Yoshikawa, Takaki Kobayashi, Michiya Hanazaki, Kazuhiro BMC Cancer Study Protocol BACKGROUND: Recent studies demonstrated the efficacy of S-1-based adjuvant chemotherapy administered for six months after curative surgery for stage III gastric cancer; however, it is unproven whether this type of combination chemotherapy is more effective than the standard adjuvant chemotherapy of S-1 for one year. METHODS: This multicenter phase II study evaluate the efficacy and safety of adjuvant chemotherapy using S-1 plus oxaliplatin followed by S-1 for up to one year for curatively resected stage III gastric cancer in patients aged over 20 years. Treatment initially comprises oral fluoropyrimidine S-1 (80 mg/m(2)) administered twice daily for the first 2 weeks of a 3-week cycle. On day 1 of a second 3-week cycle, patients will receive 100 mg/m(2) of intravenous oxaliplatin followed by 80 mg/m(2) of S-1 (maximum 8 cycles). Then, the patients will receive 80 mg/m(2) of S-1 daily for 4 weeks, followed by 2 weeks of no chemotherapy. This 6-week cycle will be repeated during the first year after surgery. The primary endpoint is relapse-free survival for 3 years and secondary endpoints are safety, including the incidence of adverse events, and grading of neuropathy with each treatment cycle. The planned sample size of 75 patients is appropriate for this trial. The data will be analyzed on an intention-to-treat basis, assuming a two-sided test with a 5% level of significance. DISCUSSION: In contrast to previous trials, the current study involves administration of S-1 until one year after surgery in addition to prior S-1 plus oxaliplatin, and is the first study to evaluate the safety and efficacy of S-1 plus oxaliplatin followed by S-1 for up to one year in patients with curatively resected stage III gastric cancer. TRIAL REGISTRATION: This trial is registered in the University Hospital Medical Information Network’s Clinical Trials Registry (UMIN-CTR) registration number, R000029656 (https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029656). Registered January 24, 2017. BioMed Central 2018-02-13 /pmc/articles/PMC5812232/ /pubmed/29439671 http://dx.doi.org/10.1186/s12885-018-4109-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Namikawa, Tsutomu Maeda, Hiromichi Kitagawa, Hiroyuki Oba, Koji Tsuji, Akihito Yoshikawa, Takaki Kobayashi, Michiya Hanazaki, Kazuhiro Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol |
title | Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol |
title_full | Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol |
title_fullStr | Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol |
title_full_unstemmed | Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol |
title_short | Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol |
title_sort | treatment using oxaliplatin and s-1 adjuvant chemotherapy for pathological stage iii gastric cancer: a multicenter phase ii study (tosa trial) protocol |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812232/ https://www.ncbi.nlm.nih.gov/pubmed/29439671 http://dx.doi.org/10.1186/s12885-018-4109-z |
work_keys_str_mv | AT namikawatsutomu treatmentusingoxaliplatinands1adjuvantchemotherapyforpathologicalstageiiigastriccanceramulticenterphaseiistudytosatrialprotocol AT maedahiromichi treatmentusingoxaliplatinands1adjuvantchemotherapyforpathologicalstageiiigastriccanceramulticenterphaseiistudytosatrialprotocol AT kitagawahiroyuki treatmentusingoxaliplatinands1adjuvantchemotherapyforpathologicalstageiiigastriccanceramulticenterphaseiistudytosatrialprotocol AT obakoji treatmentusingoxaliplatinands1adjuvantchemotherapyforpathologicalstageiiigastriccanceramulticenterphaseiistudytosatrialprotocol AT tsujiakihito treatmentusingoxaliplatinands1adjuvantchemotherapyforpathologicalstageiiigastriccanceramulticenterphaseiistudytosatrialprotocol AT yoshikawatakaki treatmentusingoxaliplatinands1adjuvantchemotherapyforpathologicalstageiiigastriccanceramulticenterphaseiistudytosatrialprotocol AT kobayashimichiya treatmentusingoxaliplatinands1adjuvantchemotherapyforpathologicalstageiiigastriccanceramulticenterphaseiistudytosatrialprotocol AT hanazakikazuhiro treatmentusingoxaliplatinands1adjuvantchemotherapyforpathologicalstageiiigastriccanceramulticenterphaseiistudytosatrialprotocol |